Effects of five commonly used glucocorticoids on haemangioma in vitro

Clinical and Experimental Pharmacology and Physiology

Volumn 30, Issue 3, 2003, Pages 140-144

  Hasan, Q ^a   Tan, Swee T ^a,b,c   Xu, B ^d   Davis, P F ^a,d  

^a Ctr Stud/Treatm Vasc Birthmarks   (New Zealand)

^b HUTT HOSPITAL   (New Zealand)

^c Reconstructive Plastic Surgery Research Institute of New Zealand   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Angiogenesis; Glucocorticoids; Growth factors; Haemangioma; In vitro; Therapy

Indexed keywords

BETAMETHASONE; CLUSTERIN; CYTOCHROME B; CYTOKINE; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; GROWTH FACTOR; HYDROCORTISONE; INTERLEUKIN 6; METHYLPREDNISOLONE; STEROID; TRANSCRIPTION FACTOR; TRIAMCINOLONE; VASCULOTROPIN;

ANGIOGENESIS; CAPILLARY PROLIFERATION; CASE REPORT; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOCHONDRION; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR REGRESSION;

ANALYSIS OF VARIANCE; ANGIOGENESIS INDUCING AGENTS; CAPILLARIES; FEMALE; GLUCOCORTICOIDS; HEMANGIOMA; HUMANS; INFANT; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037347227     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2003.03815.x     Document Type: Conference Paper

References (24)

1. Mulliken JB. Diagnosis and natural history of hemangiomas. In: Mulliken JB, Young AE (eds). Vascular Birthmarks: Hemangiomas and Vascular Malformations. WB Saunders, Philadelphia. 1988; 41-62.
2. Vikkula M, Boon LM, Mulliken JB, Olsen BR. Molecular basis of vascular anomalies. Trends Cardiovasc. Med. 1998; 5: 281-92.
3. Tan ST, Velickovic M, Rüger BM. Davis PF. Cellular and extracellular markers of hemangioma. Plast. Reconstr. Surg. 2000; 106: 529-38.
4. Takahashi K, Mulliken JB, Kozakewich HPW, Rogers RA, Folkman J, Ezekowitz RAB. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J. Clin. Invest. 1994; 93: 2357-64.
5. Jang Y-C, Arumugam S, Ferguson M, Gibran NS, Isik FF. Changes in matrix composition of human hemangiomas. J. Surg. Res. 1998; 80: 9-15.
6. Chang J, Most D, Bresnick S et al. Proliferative hemangiomas: Analysis of cytokine gene expression and angiogenesis. Plast. Reconstr. Surg. 1999; 103: 1-9.
7. Mulliken JB, Boon LM, Takahashi K, Ohlms LA, Folkman J, Ezekowitz AB. Pharmacologic therapy for endangering hemangiomas. Curr. Opin. Dermatol. 1995; 109-13.
8. Folkman J, D'Amore PA. Blood vessel formation: What is the molecular basis? Cell 1996; 87: 1153-5.
9. Bielenberg DR, Bucana CD, Sanchez R, Mulliken J, Folkman J, Fidler IJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogeneous angiogensis inhibitor, IFN-β. Int. J. Oncol. 1999; 14: 401-8.
10. Razon MJ, Kraling BM, Mulliken JB, Bischoff J. Increased apoptosis coincides with onset of involution of infantile hemangioma. Microcirculation 1998; 5: 189-95.
11. Zamzami N, Kroemer G. The mitochondrion in apoptosis: How Pandora's box opens. Nat. Rev. Mol. Cell. Biol. 2001; 2: 67-71.
12. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: Histochemical and molecular changes. Pediatrics 2000; 105: 117-21.
13. Hasan Q, Tan ST, Gush J, Davis PF. Altered mitochondrial cytochrome b gene expression during the regression of hemangioma. Plast. Reconstr. Surg. 2001; 108: 1471-6.
14. Hasan Q, Rüger BM, Tan ST, Gush J, Davis PF. Clusterin/ApoJ expression during the development of hemangioma. Hum. Pathol. 2000; 31: 691-7.
15. Wong P, Pineault J, Lakins J et al. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J. Biol. Chem. 1993; 268: 5021-31.
16. Tan ST, Hasan Q, Velickovic M, Rüger BM, Davis RPF, Davis PF. A novel in vitro human model of hemangioma. Mod. Pathol. 2000; 13: 92-9.
17. Davis PF, He Y, Furneaux RH, Johnston PS, Rüger BM, Slim GC. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc. Res. 1997; 54: 178-82.
18. Hasan Q, Dunbar PR, Murray-McIntosh RP, Neale TJ. Transforming growth factor β in human glomerulonephropathies. Nephrology 1998; 4: 353-9.
19. Pepper MS, Ferrara N, Orci L, Mantesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 1991; 181: 902-6.
20. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985; 230: 1375-8.
21. Hirano T, Akira S, Taga T, Kishimoto T. Biology and clinical aspects of interleukin 6. Immunol. Today 1990; 11: 443-9.
22. Almawi WY, Beyhum HN, Rahme AA, Rieder MJ. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J. Leukoc. Biol. 1996; 60: 563-72.
23. Breuninger LM, Dempsey WL, Uhl J, Murasco DM. Hydrocortisone regulation of IL-6 protein production by purified population of human peripheral blood monocytes. Clin. Immunol. Immunopathol. 1993; 69: 205-14.
24. Ray A, Zhang D-H, Siegel MD, Ray P. Regulation of interleukin-6 gene expression by steroids. Ann. N.Y. Acad. Sci. 1995; 762: 79-87.